Oric Pharmaceuticals, Inc.
For the period ended Jun 30, 2025. Filed Aug 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 12, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Item 5. Other Information.
Securities Trading Arrangements of Directors and Executive Officers
During the last fiscal quarter, certain directors and officers, as defined in Rule 16a-1(f), adopted a “Rule 10b5-1 trading arrangement” as defined in Regulation S-K Item 408, as follows:
On June 21, 2025, Jacob M. Chacko, M.D., our President and Chief Executive Officer, adopted a “Rule 10b5-1 trading arrangement” providing for the sale from time to time of an aggregate of up to 251,000 shares of our common stock. The trading arrangement is intended to satisfy the affirmative defense in Rule 10b5-1(c). The duration of the trading arrangement is from September 22, 2025 until June 30, 2026, or earlier if all transactions under the trading arrangement are completed.
On June 24, 2025, Dominic Piscitelli, our Chief Financial Officer, adopted a “Rule 10b5-1 trading arrangement” providing for the sale from time to time of an aggregate of up to 140,000 shares of our common stock. The trading arrangement is intended to satisfy the affirmative defense in Rule 10b5-1(c). The duration of the trading arrangement is from October 1, 2025 until June 30, 2026, or earlier if all transactions under the trading arrangement are completed.
On June 27, 2025, Mardi C. Dier, a member of the board of directors, adopted a “Rule 10b5-1 trading arrangement” providing for the sale from time to time of an aggregate of up to 114,383 shares of our common stock. The trading arrangement is intended to satisfy the affirmative defense in Rule 10b5-1(c). The duration of the trading arrangement is from September 30, 2025 until June 30, 2026, or earlier if all transactions under the trading arrangement are completed.
Except as described above, no officers or directors, as defined in Rule 16a-1(f), adopted and/orterminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” each as defined in Regulation S-K Item 408, during the last fiscal quarter.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.